

Andrew Grey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6129486/publications.pdf>

Version: 2024-02-01

180
papers

9,657
citations

57681

46
h-index

45040

94
g-index

197
all docs

197
docs citations

197
times ranked

9835
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized trial alerting authors, with or without coauthors or editors, that research they cited in systematic reviews and guidelines has been retracted. <i>Accountability in Research</i> , 2024, 31, 14-37.	1.6	5
2	Citation of retracted publications: A challenging problem. <i>Accountability in Research</i> , 2022, 29, 18-25.	1.6	31
3	Decreased thyroid FNA but increased ultrasound: Is the trade-off worthwhile?. <i>Clinical Endocrinology</i> , 2022, 96, 922-922.	1.2	0
4	Timeliness and content of retraction notices for publications by a single research group. <i>Accountability in Research</i> , 2022, 29, 347-378.	1.6	13
5	Diversity of invited speakers at endocrinology conferences. <i>Clinical Endocrinology</i> , 2022, 96, 907-913.	1.2	3
6	Nonoperative Management of Mild Primary Hyperparathyroidism: A Reasonable, Evidence-Based Option. <i>Annals of Internal Medicine</i> , 2022, , .	2.0	0
7	Correcting the scientific record – A broken system?. <i>Accountability in Research</i> , 2021, 28, 265-279.	1.6	10
8	Population vitamin D supplementation in UK adults: too much of nothing?. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 7-12.	0.3	2
9	Participant withdrawals were unusually distributed in randomized trials with integrity concerns: a statistical investigation. <i>Journal of Clinical Epidemiology</i> , 2021, 131, 22-29.	2.4	7
10	Representation of Women as Authors of Rheumatology Research Articles. <i>Arthritis and Rheumatology</i> , 2021, 73, 162-167.	2.9	23
11	Clinical trial registry documents and publication integrity. <i>Accountability in Research</i> , 2021, 28, 149-161.	1.6	6
12	Vitamin D supplementation and testing in the UK: costly but ineffective?. <i>BMJ, The</i> , 2021, 372, n484.	3.0	8
13	Prevalence of biochemical osteomalacia in adults undergoing vitamin D testing. <i>Clinical Endocrinology</i> , 2021, 95, 74-83.	1.2	4
14	Identical summary statistics were uncommon in randomized trials and cohort studies. <i>Journal of Clinical Epidemiology</i> , 2021, 136, 180-188.	2.4	5
15	Impact of grouping serial journal articles by disease category: analysis of article placement order in <i>ARD</i> 2013–2019. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 545-546.	0.5	0
16	Vitamin D deficiency, supplementation and testing: have we got it right in New Zealand?. <i>New Zealand Medical Journal</i> , 2021, 134, 86-95.	0.5	0
17	Assessing and Raising Concerns About Duplicate Publication, Authorship Transgressions and Data Errors in a Body of Preclinical Research. <i>Science and Engineering Ethics</i> , 2020, 26, 2069-2096.	1.7	14
18	Check for publication integrity before misconduct. <i>Nature</i> , 2020, 577, 167-169.	13.7	64

#	ARTICLE	IF	CITATIONS
19	Empirically generated reference proportions for baseline p values from rounded summary statistics. <i>Anaesthesia</i> , 2020, 75, 1685-1687.	1.8	16
20	Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1040-1047.	3.1	6
21	Concerns About the Integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) Report, <i>Am J Med.</i> 2004;117:549-555. <i>American Journal of Medicine</i> , 2020, 133, e311-e314.	0.6	4
22	Article placement order in rheumatology journals: a content analysis. <i>BMJ Open</i> , 2020, 10, e034550.	0.8	3
23	Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1641-e1647.	1.8	28
24	Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 3-11.	3.1	14
25	25-Hydroxyvitamin D – Should labs be measuring it?. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 188-189.	0.8	7
26	Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. <i>Calcified Tissue International</i> , 2019, 105, 423-429.	1.5	3
27	Correcting Meta-analyses and Reviews Affected by Retracted Research. <i>JAMA Internal Medicine</i> , 2019, 179, 1005.	2.6	1
28	Vitamin D supplementation and musculoskeletal health – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 88-89.	5.5	3
29	Baseline P value distributions in randomized trials were uniform for continuous but not categorical variables. <i>Journal of Clinical Epidemiology</i> , 2019, 112, 67-76.	2.4	16
30	Rounding, but not randomization method, non-normality, or correlation, affected baseline P-value distributions in randomized trials. <i>Journal of Clinical Epidemiology</i> , 2019, 110, 50-62.	2.4	18
31	Publication rates after the first retraction for biomedical researchers with multiple retracted publications. <i>Accountability in Research</i> , 2019, 26, 277-287.	1.6	11
32	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1248-1253.	3.1	13
33	Quality of reports of investigations of research integrity by academic institutions. <i>Research Integrity and Peer Review</i> , 2019, 4, 3.	2.2	23
34	An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature. <i>BMJ Open</i> , 2019, 9, e031909.	0.8	36
35	Evaluating ethics oversight during assessment of research integrity. <i>Research Integrity and Peer Review</i> , 2019, 4, 22.	2.2	1
36	Concerns About the Integrity of Sato et al. <i>Am J Med.</i> 2005;118:1250-1255. <i>American Journal of Medicine</i> , 2018, 131, e107-e108.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Lack of Evidence that Soluble Urate Directly Influences Bone Remodelling: A Laboratory and Clinical Study. <i>Calcified Tissue International</i> , 2018, 102, 73-84.	1.5	4
38	Outcomes, Interventions and Funding in Randomised Research Published in High-Impact Journals. <i>Trials</i> , 2018, 19, 592.	0.7	3
39	Enough data to draw conclusions about vitamin D and bone health. <i>BMJ: British Medical Journal</i> , 2018, 363, k4755.	2.4	0
40	A randomised investigation of journal responses to academic and journalist enquiry about possible scientific misconduct. <i>BMC Research Notes</i> , 2018, 11, 521.	0.6	7
41	Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 847-858.	5.5	303
42	Assessment of research waste part 2: wrong study populations- an exemplar of baseline vitamin D status of participants in trials of vitamin D supplementation. <i>BMC Medical Research Methodology</i> , 2018, 18, 101.	1.4	27
43	Assessment of research waste part 1: an exemplar from examining study design, surrogate and clinical endpoints in studies of calcium intake and vitamin D supplementation. <i>BMC Medical Research Methodology</i> , 2018, 18, 103.	1.4	9
44	A closer look at SCOOP: screening for fracture prevention. <i>Lancet</i> , 2018, 392, 551-552.	6.3	1
45	Inaccurate retraction notice for meta-analysis by Iwamoto et al. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 263-263.	1.0	2
46	Neglect or good practice? Authors' reply to letters by Rhein and Degner. <i>BMJ: British Medical Journal</i> , 2017, 356, j716.	2.4	0
47	Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. <i>BMJ Open</i> , 2017, 7, e013703.	0.8	13
48	Enhancing treatment effectiveness through social modelling: A pilot study. <i>Psychology and Health</i> , 2017, 32, 626-637.	1.2	7
49	Cessation of strontium ranelate supply. <i>BMJ: British Medical Journal</i> , 2017, 357, j2580.	2.4	3
50	Maintaining Order in Osteoporosis Treatments. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1147-1147.	3.1	1
51	Conflicts of interest and expertise of independent commenters in news stories about medical research. <i>Cmaj</i> , 2017, 189, E553-E559.	0.9	11
52	Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. <i>Cmaj</i> , 2017, 189, E1130-E1136.	0.9	34
53	Are more trials of calcium supplements really needed?. <i>Osteoporosis International</i> , 2017, 28, 2729-2730.	1.3	1
54	The Impact of 3-D Models versus Animations on Perceptions of Osteoporosis and Treatment Motivation: A Randomised Trial. <i>Annals of Behavioral Medicine</i> , 2017, 51, 899-911.	1.7	9

#	ARTICLE	IF	CITATIONS
55	Durability of Response to Zoledronate Treatment and Competing Mortality in Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 753-756.	3.1	33
56	Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention. <i>Osteoporosis International</i> , 2017, 28, 733-734.	1.3	7
57	Reporting of conflicts of interest in oral presentations at medical conferences: a delegate-based prospective observational study. <i>BMJ Open</i> , 2017, 7, e017019.	0.8	19
58	Reduced Bone Density and Cortical Bone Indices in Female Adiponectin-Knockout Mice. <i>Endocrinology</i> , 2016, 157, 3550-3561.	1.4	35
59	Management recommendations for osteoporosis in clinical guidelines. <i>Clinical Endocrinology</i> , 2016, 84, 687-692.	1.2	15
60	Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency. <i>BMJ</i> , The, 2016, 354, i5109.	3.0	21
61	Should adults take vitamin D supplements to prevent disease?. <i>BMJ</i> , The, 2016, 355, i6201.	3.0	28
62	Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. <i>Neurology</i> , 2016, 87, 2391-2402.	1.5	92
63	Impact of brand or generic labeling on medication effectiveness and side effects.. <i>Health Psychology</i> , 2016, 35, 187-190.	1.3	52
64	We read spam a lot: prospective cohort study of unsolicited and unwanted academic invitations. <i>BMJ</i> , The, 2016, 355, i5383.	3.0	19
65	News coverage of clinical research. <i>BMJ</i> , The, 2016, 352, i1177.	3.0	2
66	Inaccurate dissemination of the MAVIDOS trial results. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 481.	5.5	2
67	Errors in NOF meta-analyses of calcium and vitamin D supplements. <i>Osteoporosis International</i> , 2016, 27, 2637-2639.	1.3	5
68	Vitamin D supplements do not prevent falls. <i>BMJ</i> , The, 2016, 353, i3005.	3.0	3
69	Intravenous zoledronate for osteoporosis: less might be more. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 119-123.	1.2	10
70	3-D bone models to improve treatment initiation among patients with osteoporosis: A randomised controlled pilot trial. <i>Psychology and Health</i> , 2016, 31, 487-497.	1.2	15
71	Osteoporosis and Fracture Risk in Men with Prostate Cancer. <i>European Urology</i> , 2016, 69, 1026-1027.	0.9	1
72	Changing perceptions and efficacy of generic medicines: An intervention study.. <i>Health Psychology</i> , 2016, 35, 1246-1253.	1.3	15

#	ARTICLE	IF	CITATIONS
73	Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFR β . PLoS ONE, 2016, 11, e0164727.	1.1	5
74	Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open, 2015, 5, e008915.	0.8	127
75	Different outcomes of meta-analyses and data inconsistency: response to comments by Pfeifer. Archives of Osteoporosis, 2015, 10, 43.	1.0	3
76	High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information-seeking about medication. Pharmacoepidemiology and Drug Safety, 2015, 24, 592-599.	0.9	32
77	Hypertrophic osteoarthropathy with imatinib therapy. Internal Medicine Journal, 2015, 45, 1088-1090.	0.5	1
78	Reporting of Limitations of Observational Research. JAMA Internal Medicine, 2015, 175, 1571.	2.6	39
79	Responses of Specialist Societies to Evidence for Reversal of Practice. JAMA Internal Medicine, 2015, 175, 845.	2.6	18
80	Web of industry, advocacy, and academia in the management of osteoporosis. BMJ, The, 2015, 351, h3170.	3.0	27
81	The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia, 2015, 58, 2238-2246.	2.9	104
82	Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ, The, 2015, 351, h4183.	3.0	272
83	Calcium intake and risk of fracture: systematic review. BMJ, The, 2015, 351, h4580.	3.0	241
84	Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?. Climacteric, 2015, 18, 22-31.	1.1	44
85	Inconsistent data in text and tables. Osteoporosis International, 2015, 26, 2713-2713.	1.3	4
86	Vitamin D Supplements and the Risk of Falls. JAMA Internal Medicine, 2015, 175, 1723.	2.6	4
87	Everolimus and Zoledronic Acid in Patients With Renal Cell Carcinoma With Bone Metastases: A Randomized First-Line Phase II Trial. Clinical Genitourinary Cancer, 2015, 13, 50-58.	0.9	34
88	Diabetes Medications and Bone. Current Osteoporosis Reports, 2015, 13, 35-40.	1.5	6
89	Skeletal health in adults with HIV infection. Lancet Diabetes and Endocrinology, the, 2015, 3, 63-74.	5.5	36
90	Adverse skeletal effects of drugs "beyond Glucocorticoids. Clinical Endocrinology, 2015, 82, 12-22.	1.2	8

#	ARTICLE	IF	CITATIONS
91	Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access Dataset. PLoS ONE, 2015, 10, e0139975.	1.1	10
92	Media Coverage, Journal Press Releases and Editorials Associated with Randomized and Observational Studies in High-Impact Medical Journals: A Cohort Study. PLoS ONE, 2015, 10, e0145294.	1.1	13
93	Press Releases Issued by Supplements Industry Organisations and Non-Industry Organisations in Response to Publication of Clinical Research Findings: A Case-Control Study. PLoS ONE, 2014, 9, e101533.	1.1	6
94	Authors' reply to MacDonald and Etminan. BMJ, The, 2014, 349, g5523-g5523.	3.0	0
95	Enhanced osteoblastogenesis in three-dimensional collagen gels. BoneKey Reports, 2014, 3, 560.	2.7	27
96	Calcium supplements associated with increased risk of cardiovascular death in men but not women. Evidence-based Nursing, 2014, 17, 90-90.	0.1	2
97	Differences in Overlapping Meta-Analyses of Vitamin D Supplements and Falls. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4265-4272.	1.8	53
98	A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. BMJ Open, 2014, 4, e005787.	0.8	30
99	Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial. Journal of Bone and Mineral Research, 2014, 29, 166-172.	3.1	21
100	Clinical Trial Evidence and Use of Fish Oil Supplements. JAMA Internal Medicine, 2014, 174, 460.	2.6	49
101	Vitamin D supplements and bone mineral density – Authors' reply. Lancet, The, 2014, 383, 1293-1294.	6.3	1
102	Vitamin D supplementation and falls: a trial sequential meta-analysis. Lancet Diabetes and Endocrinology, the, 2014, 2, 573-580.	5.5	149
103	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes and Endocrinology, the, 2014, 2, 307-320.	5.5	371
104	Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet, The, 2014, 383, 146-155.	6.3	497
105	Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis , , . American Journal of Clinical Nutrition, 2014, 100, 746-755.	2.2	229
106	Vitamin D and falls – Authors' reply. Lancet Diabetes and Endocrinology, the, 2014, 2, 541.	5.5	0
107	Unhelpful information about adverse drug reactions. BMJ, The, 2014, 349, g5019-g5019.	3.0	52
108	The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. European Journal of Endocrinology, 2014, 170, 255-262.	1.9	37

#	ARTICLE	IF	CITATIONS
109	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 364-365.	5.5	9
110	How common are symptoms? Evidence from a New Zealand national telephone survey. <i>BMJ Open</i> , 2014, 4, e005374-e005374.	0.8	87
111	Results of Observational Studies: Analysis of Findings from the Nurses' Health Study. <i>PLoS ONE</i> , 2014, 9, e110403.	1.1	21
112	A Case Study of Discordant Overlapping Meta-Analyses: Vitamin D Supplements and Fracture. <i>PLoS ONE</i> , 2014, 9, e115934.	1.1	47
113	Integrating micro CT indices, CT imaging and computational modelling to assess the mechanical performance of fluoride treated bone. <i>Medical Engineering and Physics</i> , 2013, 35, 1793-1800.	0.8	7
114	The effect of treatments for osteoporosis on mortality. <i>Osteoporosis International</i> , 2013, 24, 1-6.	1.3	45
115	The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. <i>Osteoporosis International</i> , 2013, 24, 349-354.	1.3	20
116	Calcium supplements and cardiovascular risk: 5 years on. <i>Therapeutic Advances in Drug Safety</i> , 2013, 4, 199-210.	1.0	55
117	Discrepancies in predicted fracture risk in elderly people. <i>BMJ</i> , 2013, 346, e8669-e8669.	3.0	28
118	Low-dose Fluoride in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2301-2307.	1.8	20
119	Bone metabolism during long-term treatment with imatinib. <i>Leukemia and Lymphoma</i> , 2013, 54, 1783-1785.	0.6	6
120	An inappropriate response?. <i>BMJ</i> , 2013, 346, f942-f942.	3.0	3
121	Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2012, 166, 1087-1091.	1.9	43
122	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1922-1928.	1.8	50
123	Pioglitazone in acromegaly – an open-label, prospective study. <i>Clinical Endocrinology</i> , 2012, 77, 575-578.	1.2	7
124	Nonsurgical management of mild primary hyperparathyroidism – a reasonable option. <i>Clinical Endocrinology</i> , 2012, 77, 639-644.	1.2	9
125	Differing perceptions of intervention thresholds for fracture risk: a survey of patients and doctors. <i>Osteoporosis International</i> , 2012, 23, 2135-2140.	1.3	28
126	Five years of anti-resorptive activity after a single dose of zoledronate – Results from a randomized double-blind placebo-controlled trial. <i>Bone</i> , 2012, 50, 1389-1393.	1.4	83

#	ARTICLE	IF	CITATIONS
127	Peripartum nutrition and adult bone health. <i>Bone</i> , 2012, 51, 185.	1.4	0
128	Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 286-292.	1.8	43
129	Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1144-1149.	2.2	243
130	Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. <i>BMJ: British Medical Journal</i> , 2011, 342, d2040-d2040.	2.4	740
131	The atypical anti-psychotic clozapine decreases bone mass in rats in vivo. <i>Schizophrenia Research</i> , 2011, 126, 291-297.	1.1	17
132	The skeletal effects of the tyrosine kinase inhibitor nilotinib. <i>Bone</i> , 2011, 49, 281-289.	1.4	40
133	The skeletal effects of the tyrosine kinase inhibitor nilotinib. <i>Bone</i> , 2011, 49, 1119.	1.4	0
134	Calcium supplementation: Balancing the cardiovascular risks. <i>Maturitas</i> , 2011, 69, 289-295.	1.0	34
135	Decreased bone density in men on methadone maintenance therapy. <i>Addiction</i> , 2011, 106, 349-354.	1.7	53
136	Calcium supplements and cardiovascular disease - picking the spin. <i>International Journal of Clinical Practice</i> , 2011, 65, 226-227.	0.8	3
137	Cardiovascular effects of calcium supplementation. <i>Osteoporosis International</i> , 2011, 22, 1649-1658.	1.3	93
138	Re: The calcium scare: what would Austin Bradford Hill have thought?. <i>Osteoporosis International</i> , 2011, 22, 3079-3080.	1.3	8
139	Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2251-2255.	3.1	57
140	Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1653-1662.	1.8	85
141	Disparate Outcomes from Applying U.K. and U.S. Osteoporosis Treatment Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1856-1860.	1.8	36
142	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. <i>BMJ: British Medical Journal</i> , 2010, 341, c3691-c3691.	2.4	931
143	Evidence for a role for the p110 α isoform of PI3K in skeletal function. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 564-569.	1.0	11
144	Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1131-1136.	1.8	65

#	ARTICLE	IF	CITATIONS
145	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 538-544.	1.8	100
146	Actions of fibroblast growth factor-8 in bone cells in vitro. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E142-E150.	1.8	24
147	Fatty Acids and Bone. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2009, 7, 210-215.	1.3	3
148	Effect of calcium supplementation on hip fractures: reply to correspondence. <i>Osteoporosis International</i> , 2009, 20, 835-836.	1.3	4
149	Thiazolidinedione-induced skeletal fragility – mechanisms and implications. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 275-284.	2.2	74
150	Skeletal consequences of thiazolidinedione therapy. <i>Osteoporosis International</i> , 2008, 19, 129-137.	1.3	197
151	The Peroxisome Proliferator-Activated Receptor- γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1305-1310.	1.8	399
152	Emerging pharmacologic therapies for osteoporosis. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 493-508.	1.0	24
153	Activation of Peroxisome Proliferator-Activated Receptor γ (PPAR γ) by Rosiglitazone Suppresses Components of the Insulin-Like Growth Factor Regulatory System in Vitro and in Vivo. <i>Endocrinology</i> , 2007, 148, 903-911.	1.4	130
154	Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1679-1689.	3.1	110
155	Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway. <i>Molecular and Cellular Endocrinology</i> , 2006, 251, 96-102.	1.6	70
156	Calcium supplementation does not affect CRP levels in postmenopausal women – a randomized controlled trial. <i>Osteoporosis International</i> , 2006, 17, 1141-1145.	1.3	15
157	Imatinib Mesylate, Increased Bone Formation, and Secondary Hyperparathyroidism. <i>New England Journal of Medicine</i> , 2006, 355, 2494-2495.	13.9	59
158	Differences between the bisphosphonates for the prevention and treatment of osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 77-86.	0.9	21
159	Deletion of Aspartate 182 in OPG Causes Juvenile Paget' Disease by Impairing Both Protein Secretion and Binding to RANKL. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 438-445.	3.1	39
160	Lactoferrin - A Novel Bone Growth Factor. <i>Clinical Medicine and Research</i> , 2005, 3, 93-101.	0.4	142
161	Vitamin D Repletion in Patients with Primary Hyperparathyroidism and Coexistent Vitamin D Insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2122-2126.	1.8	228
162	Emerging and potential therapies for osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 265-278.	1.9	20

#	ARTICLE	IF	CITATIONS
163	The Low-Density Lipoprotein Receptor-Related Protein 1 Is a Mitogenic Receptor for Lactoferrin in Osteoblastic Cells. <i>Molecular Endocrinology</i> , 2004, 18, 2268-2278.	3.7	154
164	Osteoblastic Cells Express Phospholipid Receptors and Phosphatases and Proliferate in Response to Sphingosine-1-Phosphate. <i>Calcified Tissue International</i> , 2004, 74, 542-550.	1.5	46
165	Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. <i>Biochemical and Biophysical Research Communications</i> , 2004, 318, 240-246.	1.0	47
166	Parallel Phosphatidylinositol-3 Kinase and p42/44 Mitogen-Activated Protein Kinase Signaling Pathways Subserve the Mitogenic and Antiapoptotic Actions of Insulin-Like Growth Factor I in Osteoblastic Cells. <i>Endocrinology</i> , 2003, 144, 4886-4893.	1.4	100
167	The Phospholipids Sphingosine-1-Phosphate and Lysophosphatidic Acid Prevent Apoptosis in Osteoblastic Cells via a Signaling Pathway Involving Gi Proteins and Phosphatidylinositol-3 Kinase. <i>Endocrinology</i> , 2002, 143, 4755-4763.	1.4	104
168	Primary Hyperparathyroidism: Medical Management. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2002, 1, 35-42.	1.3	0
169	Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001, 280, E405-E412.	1.8	68
170	Lysophosphatidic Acid Is an Osteoblast Mitogen Whose Proliferative Actions Involve Gi Proteins and Protein Kinase C, But Not P42/44 Mitogen-Activated Protein Kinases*. <i>Endocrinology</i> , 2001, 142, 1098-1106.	1.4	57
171	A Potential Role for Adrenomedullin as a Local Regulator of Bone Growth. <i>Endocrinology</i> , 2001, 142, 1849-1857.	1.4	57
172	A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo. <i>Endocrinology</i> , 1999, 140, 4683-4690.	1.4	144
173	Primary Hyperparathyroidism: To Lose Bone. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 2127-2127.	3.1	3
174	Moderate Dietary Salt Restriction Does Not Alter Insulin Resistance or Serum Lipids in Normal Men. <i>American Journal of Hypertension</i> , 1996, 9, 317-322.	1.0	43
175	Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. <i>Clinical Endocrinology</i> , 1996, 44, 293-296.	1.2	44
176	Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption—a clinical research center study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 3450-3454.	1.8	121
177	Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption—a clinical research center study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 3450-3454.	1.8	98
178	Body Weight and Bone Mineral Density in Hyperparathyroidism. <i>Annals of Internal Medicine</i> , 1995, 123, 732.	2.0	26
179	Lysophosphatidic Acid Is an Osteoblast Mitogen Whose Proliferative Actions Involve Gi Proteins and Protein Kinase C, But Not P42/44 Mitogen-Activated Protein Kinases. , 0, .		18
180	A Potential Role for Adrenomedullin as a Local Regulator of Bone Growth. , 0, .		15